



CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION

- **Title:** Clinical Practice guideline for the management of patients with Atrial Fibrillation.
- Author: Peru. EsSalud Social Security. Health Technology Assessment and Research Institute (IETSI in Spanish)
- **Publication date:** *September/2018*
- **Publishing house:** EsSalud Social Security. "Health Technology Assessment and Research Institute (IETSI in Spanish)
- Abstract:

Background: This paper abstracts the Clinical Practice guideline (CPG) for the management of patients with Atrial Fibrillation in the Peruvian Social Security (EsSalud).

Objective: to provide evidence-based clinical recommendations for the management of Atrial Fibrillation in EsSalud.

Methods: a guideline task force (GTF) was formed with cardiologists and methodologists. The group proposed 9 clinical questions to be answered in this Clinical practice guideline (CPG). Systematic searches of preview reviews were performed and when it was necessary, primary studies from PubMed and CENTRAL during 2018 were reviewed. The evidence was selected to answer each proposed clinical question. Certainty of evidence was evaluated using Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. In periodical work sessions, the group used GRADE methodology for reviewing the evidence and formulating recommendations, good clinical practice items and the management flowchart. Finally, the CPG was approved by Resolution N^o 008-IETSI-ESSALUD-2018.

Results: This CPG approached 9 clinical questions about one topic: management. Based on these questions; six strong recommendations, six weak recommendations, 29 good clinical practice items and two flowcharts were formulated.

Conclusion: This paper abstracts the methodology and evidence-based conclusions about the CPG for the management of Atrial Fibrillation in EsSalud. **Key words:** Practice Guideline, GRADE Approach, Atrial Fibrillation.

• PICO questions for CPG:

PREVENTION			
Question 1: In patients with nonvalvular atrial fibrillation, what is the best risk index			
to predict thromboembolic events (ATRIA o CHA2DS2-VASc)?			
POPULATION	INTERVENTION	COMPARATOR	OUTCOME(S)





Detiente with			C statistic for	
-Patients with	- ATRIA	- CHA2DS2-VASc	- C-statistic for	
Atrial Fibrillation			thromboembolic	
			events	
Question 2: In pat	ients with AF, which	antithrombotic the	erapy should be provided	
for the prevention	of thromboembolic	events?		
POPULATION	INTERVENTION	COMPARATOR	OUTCOME(S)	
-Patients with	- Anticoagulants	- Antiplatelet	- Thrombolembolic	
Atrial Fibrillation	(Vitamin K	agents	events	
	inhibitors)		- Bleeding	
			- Mortality	
Question 3: In pati	ents with AF, which	risk index should be	used to predict bleeding?	
POPULATION	INTERVENTION	COMPARATOR	OUTCOME(S)	
- Patients with	- HAS-BLED	- ATRIA	- C-statistic for major	
Atrial			bleeding.	
Fibrillation				
using				
anticoagulation				
therapy.				
Question 4: In pati	ents with AF, should	the left atrial appe	ndage occlusion (LAO) be	
performed to prevent thromboembolic events?				
POPULATION	INTERVENTION	COMPARATOR	OUTCOME(S)	
- Patients with	- LAO	- Antithrombotic	- Mortality	
Atrial Fibrillation		therapy	- thrombolembolic	
			events	
			- Bleeding	

TREATMENT			
Question 5: In patients with AF, should one opt for rhythm control strategies or rate control strategies?			
POPULATION	INTERVENTION	COMPARATOR	OUTCOME(S)
- Patients with	- Rhythm control	- Rate control	- Mortality
Atrial Fibrillation	strategies	strategies	 Quality of life
			- Severe adverse
			events
			- CVD
			(Cerebrovascular
			disease)
Question 6: In patients with AF in whom a rate control strategy is used, which rate			
control strategy should be used?			
POPULATION	INTERVENTION	COMPARATOR	OUTCOME(S)
- Patients with	- beta-blocks, non-	- Placebo	- Mortality
Atrial Fibrillation	dihydropyridine		- Quality of life





	calcium channel		- Severe adverse
	blockers, digoxin.		events
	DIOCKETS, UIGOAITI.		- Rate control
Question 7: In natio	nts with AF who need	a rhythm control str	
control strategy sho			ategy, which mythin
POPULATION	INTERVENTION	COMPARATOR	OUTCOME(S)
- Patients with AF	- Sotalol	- No Sotalol	- Mortality
who need			- Withdrawal due
rhythm			to adverse
maintenance			effects
			- Pro-arrhythmic
			effects.
			- Recurrence of
			atrial fibrillation
- Patients with AF	- IA	- Control	- Mortality
who need	Antiarrhythmics		- Withdrawal due
rhythm			to adverse
maintenance			effects
			- Pro-arrhythmic
			effects.
			Recurrence of
			atrial fibrillation
- Patients with AF	- IC	- Control	- Mortality
who need	Antiarrhythmics		- Withdrawal due
rhythm			to adverse
maintenance			effects
			- Pro-arrhythmic
			effects.
			Recurrence of
			atrial fibrillation
 Patients with AF 	- Beta blocks	- Control	- Mortality
who need			- Withdrawal due
rhythm			to adverse
maintenance			effects
			- Pro-arrhythmic
			effects.
			- Recurrence of
• • • • •			atrial fibrillation
-	nts with permanent a		
	of atrioventricular not	-	-
POPULATION	INTERVENTION	COMPARATOR	OUTCOME(S)
- Patients with	- Ablation	- Pharmacological	- No presence of
non-paroxysmal atrial fibrillation		treatment for	atrial arrhythmia or recurrence of
		rhythm control	or recurrence of atrial fibrillation



IETSI ESSalud



			 Require cardioversion Require hospitalization for cardiac cause Presence of significant bradycardia or need for pacemakers. Complications derived from ablative therapy or
			pharmacological treatment.
 Patients with non-paroxysmal atrial fibrillation 	- Ablation	 Pharmacological treatment for rhythm control 	 Recurrence of atrial fibrillation Symptomatic atrial fibrillation
Question 9: In patients with acute-onset atrial fibrillation, should emergency			
electrical cardioversion be performed?			
POPULATION	INTERVENTION	COMPARATOR	OUTCOME(S)
- Patients with	- Electrical	- Other	- Heart rate
acute-onset	cardioversion	interventions	control
atrial fibrillation			 Adverse events